Literature DB >> 31004634

Hyaluronic acid - dihydroartemisinin conjugate: Synthesis, characterization and in vitro evaluation in lung cancer cells.

Robin Kumar1, Mamta Singh1, Jairam Meena1, Priyank Singhvi1, Durairaj Thiyagarajan1, Ankit Saneja2, Amulya K Panda3.   

Abstract

In recent years, a great deal of attention has been given towards re-purposing and re-innovating the potential drugs. In this regard, dihydroartemisinin (DHA) has been reported to demonstrate anti-proliferative effects on various cancerous cells viz. breast, liver and lung. However, it is associated with some limitations, such as low bioavailability which is hampered by its poor aqueous solubility and its rapid metabolism in systemic circulation. Therefore, in order to overcome these limitations, we synthesized a novel hyaluronic acid-dihydroartemisinin conjugate in which the hydroxyl group of DHA was covalently linked to carboxylic group of hyaluronic acid (HA). The conjugate was successfully characterized using 1H NMR, Fourier transform infrared spectroscopy (FT-IR) and gel permeation chromatography (GPC). The synthesized conjugate self-assembled into nanoparticles in aqueous solution. The developed nanoparticles were characterized for their average size, zeta potential, Transmission Electron Microscopy (TEM), X-ray Powder Diffraction (XRD) and loading efficiency. The nanoparticles were cytotoxic to lung cancer (A549) cell line which was determined using CCK-8 cell viability assay. This was further supported by Annexin-V-FITC-Propidium iodide apoptosis assay, reactive oxygen species (ROS) production and mitochondrial membrane potential (MMP) loss. Conclusively, present findings demonstrate hyaluronic acid conjugates can be used to improve the therapeutic outcomes of anticancer drugs.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apoptosis; Cytotoxicity; Dihydroartemisinin; Hyaluronic acid; Nanoparticle

Mesh:

Substances:

Year:  2019        PMID: 31004634     DOI: 10.1016/j.ijbiomac.2019.04.124

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  11 in total

1.  A nanoreactor boosts chemodynamic therapy and ferroptosis for synergistic cancer therapy using molecular amplifier dihydroartemisinin.

Authors:  Xiao-Xin Yang; Xiang Xu; Mei-Fang Wang; Hua-Zhen Xu; Xing-Chun Peng; Ning Han; Ting-Ting Yu; Liu-Gen Li; Qi-Rui Li; Xiao Chen; Yu Wen; Tong-Fei Li
Journal:  J Nanobiotechnology       Date:  2022-05-14       Impact factor: 9.429

Review 2.  Perspectives and controversies regarding the use of natural products for the treatment of lung cancer.

Authors:  Tingting Wen; Lei Song; Shucheng Hua
Journal:  Cancer Med       Date:  2021-03-02       Impact factor: 4.452

Review 3.  Polymer-Drug Conjugate, a Potential Therapeutic to Combat Breast and Lung Cancer.

Authors:  Sibusiso Alven; Xhamla Nqoro; Buhle Buyana; Blessing A Aderibigbe
Journal:  Pharmaceutics       Date:  2020-04-29       Impact factor: 6.321

4.  A Hyaluronic Acid Functionalized Self-Nano-Emulsifying Drug Delivery System (SNEDDS) for Enhancement in Ciprofloxacin Targeted Delivery against Intracellular Infection.

Authors:  Rabia Arshad; Tanveer A Tabish; Maria Hassan Kiani; Ibrahim M Ibrahim; Gul Shahnaz; Abbas Rahdar; Misook Kang; Sadanand Pandey
Journal:  Nanomaterials (Basel)       Date:  2021-04-22       Impact factor: 5.076

5.  Ligand-modified homologous targeted cancer cell membrane biomimetic nanostructured lipid carriers for glioma therapy.

Authors:  Mengyu Chen; Yuexin Cui; Wenyan Hao; Yueyue Fan; Jingqiu Zhang; Qianqian Liu; Mingrui Jiang; Yang Yang; Yingzi Wang; Chunsheng Gao
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

Review 6.  Research Progress of Conjugated Nanomedicine for Cancer Treatment.

Authors:  Bin Zhao; Sa Chen; Ye Hong; Liangliang Jia; Ying Zhou; Xinyu He; Ying Wang; Zhongmin Tian; Zhe Yang; Di Gao
Journal:  Pharmaceutics       Date:  2022-07-21       Impact factor: 6.525

7.  Dihydroartemisinin remodels macrophage into an M1 phenotype via ferroptosis-mediated DNA damage.

Authors:  Liu-Gen Li; Xing-Chun Peng; Ting-Ting Yu; Hua-Zhen Xu; Ning Han; Xiao-Xin Yang; Qi-Rui Li; Jun Hu; Bin Liu; Zi-Yi Yang; Xiang Xu; Xiao Chen; Mei-Fang Wang; Tong-Fei Li
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

8.  pH-Responsive Artesunate Polymer Prodrugs with Enhanced Ablation Effect on Rodent Xenograft Colon Cancer.

Authors:  Dan-Li Hao; Ran Xie; Ge-Jing De; Hong Yi; Chen Zang; Mi-Yi Yang; Li Liu; Hai Ma; Wei-Yan Cai; Qing-He Zhao; Feng Sui; Yan-Jun Chen
Journal:  Int J Nanomedicine       Date:  2020-03-16

9.  Self-assembled dihydroartemisinin nanoparticles as a platform for cervical cancer chemotherapy.

Authors:  Yun Lu; Qian Wen; Jia Luo; Kang Xiong; ZhouXue Wu; BiQiong Wang; Yue Chen; Bo Yang; ShaoZhi Fu
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

10.  Dihydroartemisinin-Loaded Magnetic Nanoparticles for Enhanced Chemodynamic Therapy.

Authors:  Shengdi Guo; Xianxian Yao; Qin Jiang; Kuang Wang; Yuanying Zhang; Haibao Peng; Jing Tang; Wuli Yang
Journal:  Front Pharmacol       Date:  2020-03-10       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.